Dimethaid announces additions to board of directors
via COMTEX
August 24, 2004
TORONTO, Aug 24, 2004 (Canada NewsWire via COMTEX) --
Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX) has announced the appointment of additional expertise to its board of directors. Besides international licensing consultant Diane J. Kalina, whose appointment was announced earlier this month, the board has been augmented by Jeffrey H. Berg, a prominent, U.S. pharmaceutical industry analyst, and Edward E. McCormack, an independent business consultant and former chief financial officer of Novopharm Ltd. John Wiseman has resigned from the board after making an important contribution to the company's audit committee.
"These additions are part of a long-standing succession plan to continue introducing new leadership as we implement our business strategy," said Rebecca E. Keeler, president and CEO. "Those who shape our corporate direction can make more valuable contributions when they thoroughly understand our industry. And Ms. Kalina, Dr. Berg and Mr. McCormack, all represent opportunities to capitalize on fresh ideas informed by extensive real-world industry experience."
Jeffrey H. Berg is a medical-product and biopharmaceutical analyst at Crystal Research Associates, an independent research firm in New York City. Dr. Berg's 35-year career has included positions of increasing responsibility at General Foods Corporation, Johnson & Johnson's Patient Care Division and Ortho Pharmaceutical Corporation. He was a former vice president, health care, at PA Technology, a U.K.-based consultancy with operations in Princeton, New Jersey. He has also served as vice president of research at J.C. Bradford & Co (now UBS Securities), The Chicago Corporation (now ABN/Amro), M.H. Meyerson & Co., Inc (now Crown Financial), and HCFP/Brenner Securities.
For the past 14 years, Dr. Berg has headed Health Care Insights, providing consulting services to both major and emerging biomedical product companies, and has covered major medical conferences as a contributing editor to the BBI Newsletter, published by American Health Consultants. Dr. Berg holds a PhD in organic chemistry and an MBA, both from New York University. He also serves on the board of directors of Bio-Imaging Technologies, Inc.
Edward E. McCormack most recently served as president of Almad Investments Ltd, a real estate investment firm, as well as president of Beaver Power Corporation, a hydroelectric company. Between 1987 and 1999, he was senior vice president and chief financial officer and a director of Novopharm Limited, a generic drug manufacturer, as well as CFO of Novopharm Biotech Ltd. now Viventia Biotech Inc., a TSX-listed company engaged in basic cancer research.
Mr. McCormack is a chartered accountant and a graduate of the University of Toronto with a degree in commerce and finance. His financial background includes specific experience in private placements, bank financing and re- structuring, acquisitions and divestitures. He is a member of the Ontario Institute of Chartered Accountants and a director and chairman of the audit committee at Hemosol Corp. |
